Modality
Fusion Protein
MOA
SHP2i
Target
BCL-2
Pathway
STING
Obesity
Development Pipeline
Preclinical
~Aug 2013
→ ~Nov 2014
Phase 1
~Feb 2015
→ ~May 2016
Phase 2
~Aug 2016
→ ~Nov 2017
Phase 3
Feb 2018
→ Jun 2030
Phase 3Current
NCT06949096
2,451 pts·Obesity
2018-02→2025-07·Not yet recruiting
NCT06607297
1,787 pts·Obesity
2021-06→2025-05·Terminated
NCT06703857
2,895 pts·Obesity
2023-01→2030-06·Active
7,133 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-0611mo agoPh3 Readout· Obesity
2025-07-218mo agoPh3 Readout· Obesity
2030-06-134.2y awayPh3 Readout· Obesity
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Not yet…
P3
Termina…
P3
Active
Catalysts
Ph3 Readout
2025-05-06 · 11mo ago
Obesity
Ph3 Readout
2025-07-21 · 8mo ago
Obesity
Ph3 Readout
2030-06-13 · 4.2y away
Obesity
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06949096 | Phase 3 | Obesity | Not yet recr... | 2451 | HbA1c |
| NCT06607297 | Phase 3 | Obesity | Terminated | 1787 | ORR |
| NCT06703857 | Phase 3 | Obesity | Active | 2895 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |